Filipendula ulmaria (L.) Maxim. — the salicylate-bearing meadow herb that gave aspirin its name, whose phenolic heterosides, hypouricemic flavonoids, and ellagitannin-rich flowering tops support a traditional use in rheumatism, gout, and fever — and whose anti-inflammatory and antitumoral preclinical pharmacology runs far deeper than its EMA traditional-use status alone suggests.
Filipendula ulmaria is a tall herbaceous perennial of damp meadows, ditches, and riverbanks, with large leaves divided into unequal toothed leaflets, the terminal leaflet noticeably larger than the rest. Its numerous small white flowers grow in dense compound clusters and carry a characteristic fragrance traceable to methyl salicylate — the same aromatic compound found in wintergreen. The plant is melliferous (attractive to bees) and grows across nearly all of France and Europe outside the Mediterranean coastline, as well as western and northern Asia and North America. Pharmacologically, it is the flowering tops that are used — accumulating a phenolic heteroside fraction (monotropitoside, spiraeoside) alongside a substantial ellagitannin and flavonoid load.
Meadowsweet has long been part of European herbal tradition, recorded by the 19th-century French physician Cazin as a vulnerary (wound-healing), sudorific (diaphoretic), astringent, and diuretic herb, prescribed against dropsy (oedematous fluid retention) and rheumatic disorders. This traditional rheumatic and diuretic use is precisely what the modern EMA herbal monograph still recognises today, more than a century and a half later.
Meadowsweet holds an outsized place in pharmaceutical history: its former botanical name, Spiraea ulmaria, is the direct etymological source of the word "Aspirin." Around 1830, Swiss pharmacist Johann Pagenstecher extracted a compound from meadowsweet flowers that he suspected had therapeutic value; German chemist Karl Jacob Löwig subsequently confirmed it was the same salicylic acid that Italian chemist Raffaele Piria had isolated from willow bark in 1838. When Bayer's Felix Hoffmann stabilised acetylsalicylic acid in 1897, the resulting drug took its name from "a-" (acetyl) plus "-spir-" (from Spirsäure, the German name for salicylic acid, itself named for Spiraea) plus the common drug-suffix "-in" — making meadowsweet, not willow, the plant that gave the world's most widely used drug its name.
Modern phytochemical interest accelerated through the 2010s, with comprehensive UHPLC-Orbitrap mass spectrometry profiling identifying 119 distinct compounds in the flowering tops, and dedicated in vitro and in vivo studies confirming the anti-inflammatory, antioxidant, and hypouricemic pharmacology that traditional use had only inferred. It is this preclinical and traditional-use evidence base — rather than large human RCTs — that underpins meadowsweet's current EMA recognition.
⚠ Salicylate Sensitivity Warning
Meadowsweet should be avoided by anyone with a known allergy or hypersensitivity to aspirin or other salicylates. Its phenolic glycosides are chemically related to the compounds in aspirin, and although a typical infusion delivers only trace salicylate levels, cross-reactivity risk means the EMA monograph lists salicylate hypersensitivity as an explicit contraindication. Meadowsweet preparations are not intended for use beyond four consecutive weeks without medical advice.
Only the flowering tops are medicinal. Five galenical forms are documented in the primary source.
The flowering tops (sommités fleuries) contain the phenolic heteroside fraction (monotropitoside, spiraeoside), a substantial ellagitannin load (10–20% of the drug), and trace essential oil. Harvested at flowering and dried; drying conditions materially affect retention of the phenolic fraction.
Spiraeoside · Monotropitoside · Tellimagrandin · Rutoside
From the EMA Community herbal monograph and primary phytotherapy literature.[1] Not intended for use beyond 4 consecutive weeks without medical advice.
The flowering tops are dominated by phenolic heterosides, flavonoids, and ellagitannins. Bud composition and properties are absent from the source and not applicable for this species.
Antirheumatic activity attributed to phenolic heterosides such as monotropitoside, whose aglycone is methyl salicylate. This is the traditional foundation of meadowsweet's use against rheumatic disorders aggravated by humidity, and aligns with its broader salicylate-related pharmacology even though systemic salicylate exposure from the herb itself is low.
Documented anti-inflammatory activity in vitro and in vivo,[8][9] including reduction of the inflammatory cytokines IL-6 and TNF-alpha via apigenin and quercetin,[10] inhibition of both COX-1 and COX-2,[11] documented activity in gout,[13] and hypouricemic activity via xanthine oxidase inhibition reported to exceed allopurinol, attributed to spiraeoside.[14]
Antimicrobial effects documented against bacterial targets, attributed to the plant's flavonoid and broader phenolic compound content, in a screening study of Finnish plant extracts.[15]
Analgesic activity documented as a distinct property in a comprehensive phytochemical and pharmacological review of Filipendula ulmaria, separate from the antihyperalgesic data already covered under the anti-inflammatory property above.[16]
Diuretic activity with a uricosuric character — promoting renal elimination of uric acid alongside fluid output. This property pairs directly with the xanthine oxidase-inhibiting hypouricemic mechanism to give meadowsweet a dual mode of action relevant to gout and elevated uric acid.
Diaphoretic (sweat-inducing) activity specifically noted for use during colds — a traditional febrifuge application consistent with meadowsweet's long-documented use against fevers in classical European phytotherapy.
Preclinical antitumoral activity: flower extracts inhibited the growth of three human tumour cell lines — non-small-cell lung cancer (NCI-H460), melanoma (A375-C5), and breast adenocarcinoma (MCF-7).[17] This is cell-line evidence only, with no human clinical trial data, and should not be read as a cancer-treatment indication.
Reduces hepatic and renal adverse effects caused by cisplatin chemotherapy — confirmed in an animal model and LC-MS analysis, with meadowsweet extract attenuating cisplatin-induced oxidative stress in liver and kidney tissue.[18] Preclinical finding; no human chemotherapy-adjunct trial data exists.
Immunomodulating activity documented across roots, leaves, and flowers, including inhibition of reactive oxygen species production by leukocytes attributed to the tannin fraction.[19][20]
A clinico-experimental study found plant preparations from meadowsweet flowers showed activity against precancerous changes of the uterine cervix, explored as a potential adjunct in cervical cancer prevention.[21] A narrow, study-specific finding rather than an established clinical use.
Anticoagulant activity attributed to a heparin-like molecular complex found in meadowsweet flowers, which was neutralised by protamine sulfate — the same agent used to reverse heparin — indicating a genuinely heparin-like mechanism rather than a different anticoagulant pathway.[22] This is also the pharmacological basis for the explicit contraindication with heparin and heparin derivatives.
Inhibits elastase, an enzyme that degrades the structural elastin protein of connective tissue — documented in a comparative study of tannin content and elastase-inhibiting activity across Rosaceae family plants.[23]
Anti-ulcer activity demonstrated in a decoction of meadowsweet flowers in an animal model,[24] attributed to a specific flavonoid profile (spiraeoside, kaempferol 4'-O-glucoside, astragaline and hyperoside 2'-O-gallate, isoquercitrine 2'-O-gallate) and the tannin tellimagrandin II.[25]
Antioxidant activity documented in both Filipendula ulmaria and the closely related Filipendula hexapetala,[26] alongside enzyme-inhibiting activity against acetylcholinesterase and tyrosinase.[27]
Root extracts inhibit propagation of the Echo 9 virus and act as an interferon inducer — a documented but mechanistically under-characterised antiviral/immune property distinct from the broader immunomodulant activity of the aerial parts.
Indications from the EMA HMPC Community herbal monograph, traditional phytotherapy literature, and supporting preclinical pharmacology. Most indications rest on traditional use rather than dedicated human RCTs.
Meadowsweet's pharmacology rests on phenolic glycoside hydrolysis, dual COX/cytokine anti-inflammatory action, a heparin-like anticoagulant complex, and gut-microbiota-dependent metabolism of its ellagitannin fraction.
During drying and storage, the heterosides monotropitoside and spiraeoside release salicylic aldehyde — representing roughly 75% of the resulting essential oil — along with methyl salicylate and related alcohols. This is a post-harvest chemical transformation rather than a metabolic one: it explains why dried, processed meadowsweet carries a distinctive wintergreen-like aroma despite the fresh flowering tops containing only low levels of free salicylates, and underscores why drying conditions are a meaningful quality variable for standardised extracts.
Meadowsweet's anti-inflammatory action operates through inhibition of both cyclo-oxygenase isoforms (COX-1 and COX-2) — the same enzyme family targeted by NSAIDs and by aspirin itself[11] — alongside a separate, complementary pathway: apigenin and quercetin content reduces the inflammatory cytokines IL-6 and TNF-alpha in macrophage models.[10] This dual enzyme-and-cytokine mechanism gives meadowsweet a broader anti-inflammatory footprint than salicylate pharmacology alone would predict, consistent with its rich non-salicylate flavonoid and ellagitannin fraction.
A molecular complex isolated from meadowsweet flowers exhibits heparin-like anticoagulant activity, and is neutralised by protamine sulfate — the clinical antagonist used to reverse heparin overdose.[22] This is direct pharmacological evidence that the mechanism mimics heparin rather than acting through a vitamin-K-dependent or platelet pathway, and is the basis for the explicit contraindication against combining meadowsweet with heparin or heparin derivatives, and for caution with other anticoagulant and antiplatelet medications.
Meadowsweet's large ellagitannin fraction (10–20% of the dried drug) is not absorbed intact — intestinal microbiota play an important role in its bioavailability, metabolising ellagitannins into urolithins, the bioactive metabolites thought to mediate much of the downstream anti-inflammatory effect.[29] This means meadowsweet's clinical effect may vary between individuals depending on gut microbial composition, a pharmacokinetic nuance shared with other ellagitannin-rich botanicals (pomegranate, raspberry, walnut) but rarely discussed in consumer-facing herbal content.
Two salicylate-related European phytomedicines with very different evidence levels — one is aspirin's etymological namesake, the other its closest formal regulatory cousin.
Clinical Bottom Line
Choose willow bark when you want a standardised, clinically dosed salicylate analgesic with meaningful RCT backing — particularly for low back pain. Choose meadowsweet when gout, hyperuricemia, or a gentler, broader-spectrum anti-inflammatory and antioxidant botanical is the goal, understanding that its evidence base is traditional and preclinical rather than RCT-driven. The two share a salicylate-pathway heritage but are not interchangeable: meadowsweet does not deliver a standardised salicylate dose the way willow bark does, and both carry caution around concurrent anticoagulant or antiplatelet medication.
Very few adverse effects recorded overall. Salicylate-allergic individuals and those on anticoagulant therapy require special attention.